Sanara MedTech Inc. (NASDAQ:SMTI) Receives $35.00 Consensus PT from Analysts

Sanara MedTech Inc. (NASDAQ:SMTI) has received a consensus recommendation of “Reduce” from the five research firms that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating and four have given a hold rating to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $35.00.

A number of analysts have issued reports on the stock. Wall Street Zen downgraded shares of Sanara MedTech from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 1st. Weiss Ratings raised shares of Sanara MedTech from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. Zacks Research upgraded Sanara MedTech from a “strong sell” rating to a “hold” rating in a research report on Wednesday, June 10th. HC Wainwright cut Sanara MedTech from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $36.00 to $35.00 in a report on Thursday, July 30th. Finally, Lake Street Capital downgraded Sanara MedTech from a “buy” rating to a “hold” rating and set a $35.00 target price on the stock. in a research report on Thursday, July 30th.

Institutional Trading of Sanara MedTech

Large investors have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets boosted its position in shares of Sanara MedTech by 351.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,504 shares of the company’s stock valued at $48,000 after acquiring an additional 1,171 shares during the last quarter. Lazard Asset Management LLC raised its stake in Sanara MedTech by 63,100.0% during the second quarter. Lazard Asset Management LLC now owns 3,160 shares of the company’s stock valued at $89,000 after purchasing an additional 3,155 shares in the last quarter. Bank of America Corp DE raised its stake in Sanara MedTech by 44.1% during the third quarter. Bank of America Corp DE now owns 3,181 shares of the company’s stock valued at $101,000 after purchasing an additional 973 shares in the last quarter. Wells Fargo & Company MN lifted its position in Sanara MedTech by 78.1% during the fourth quarter. Wells Fargo & Company MN now owns 3,322 shares of the company’s stock valued at $78,000 after purchasing an additional 1,457 shares during the last quarter. Finally, Rhumbline Advisers lifted its position in Sanara MedTech by 14.9% during the first quarter. Rhumbline Advisers now owns 3,714 shares of the company’s stock valued at $115,000 after purchasing an additional 483 shares during the last quarter. Institutional investors own 8.10% of the company’s stock.

Sanara MedTech Price Performance

NASDAQ SMTI opened at $34.73 on Tuesday. Sanara MedTech has a 12 month low of $16.05 and a 12 month high of $35.95. The company has a current ratio of 2.58, a quick ratio of 2.30 and a debt-to-equity ratio of 5.86. The stock has a market cap of $319.17 million, a PE ratio of -9.67 and a beta of 1.16. The stock’s 50 day moving average is $30.29 and its 200 day moving average is $23.76.

Sanara MedTech (NASDAQ:SMTI) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.03). Sanara MedTech had a negative net margin of 29.15% and a positive return on equity of 29.72%. The company had revenue of $28.14 million for the quarter, compared to analysts’ expectations of $28.95 million. Research analysts predict that Sanara MedTech will post 0.16 EPS for the current fiscal year.

Sanara MedTech Company Profile

Sanara MedTech is a medical technology company focused on developing and commercializing innovative devices for ear, nose and throat (ENT) healthcare. The company’s core offering centers on minimally invasive sinus dilation systems designed to treat chronic sinusitis and related conditions. These products leverage balloon catheter technology to expand sinus pathways and improve patient outcomes while reducing recovery times. In addition to sinus solutions, the portfolio extends to procedural tools and implants for otology and cranial applications.

With its legacy rooted in the assets of a former Johnson & Johnson business, Sanara MedTech combines decades of research and development in ENT therapies.